• Nektar Therapeutics granted 45,750 non-qualified stock options and 2,775 restricted stock units on October 20, 2026.
• The awards cover 16 newly hired employees under the 2025 Inducement Plan, with vesting conditional on continued employment.
• A September 23, 2026 amendment increased shares available under the plan by 250,000 to 500,000.
• Options have eight-year terms, vesting 25% on the first grant anniversary, then 1/48 monthly over the next three years.
• Restricted stock units vest 25% following the first grant anniversary, then 1/16 quarterly over the next three years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610231615PR_NEWS_USPR_____SF79946) on October 23, 2026, and is solely responsible for the information contained therein.